{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:02Z","timestamp":1790679182847,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":1051,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.bbadis.2010.05.003","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T02:21:38Z","timestamp":1274062898000},"page":"741-748","source":"Crossref","is-referenced-by-count":198,"title":["Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease"],"prefix":"10.1016","volume":"1802","author":[{"given":"S.M.","family":"Rombach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Zwinderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kuiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"vd Bergh Weerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.M.","family":"Groener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Poorthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2010.05.003_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"WALL, Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.bbadis.2010.05.003_bib2","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry's disease : classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2010.05.003_bib3","first-page":"3733","article-title":"alpha-Galactosidase A deficiency: Fabry disease","volume":"vol 3","author":"Desnick","year":"2001"},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"Suppl 2","key":"10.1016\/j.bbadis.2010.05.003_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1012447102358","article-title":"Natural history of Fabry disease in affected males and obligate carrier females","volume":"24","author":"MacDermot","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.bbadis.2010.05.003_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"Vonscheidt","year":"1991","journal-title":"N Engl J. Med."},{"issue":"5","key":"10.1016\/j.bbadis.2010.05.003_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J. Med."},{"issue":"7","key":"10.1016\/j.bbadis.2010.05.003_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson\u2013Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.bbadis.2010.05.003_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"10.1016\/j.bbadis.2010.05.003_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"21","key":"10.1016\/j.bbadis.2010.05.003_bib13","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2008.02.050","article-title":"Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results","volume":"51","author":"Linthorst","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.bbadis.2010.05.003_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9378(90)90410-9","article-title":"Demonstration of Fabry's disease deposits in placenta","volume":"162","author":"Popli","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"447","key":"10.1016\/j.bbadis.2010.05.003_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"issue":"4","key":"10.1016\/j.bbadis.2010.05.003_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8","key":"10.1016\/j.bbadis.2010.05.003_bib20","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bbadis.2010.05.003_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-006-0340-x","article-title":"Structural and functional changes in peripheral vasculature of Fabry patients","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"451","key":"10.1016\/j.bbadis.2010.05.003_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/08035320600618924","article-title":"Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease","volume":"95","author":"Barbey","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"issue":"439","key":"10.1016\/j.bbadis.2010.05.003_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1651-2227.2002.tb03113.x","article-title":"Arterial remodelling in Fabry disease","volume":"91","author":"Boutouyrie","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.bbadis.2010.05.003_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.bbadis.2010.05.003_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.bbadis.2010.05.003_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0002-9149(87)91133-7","article-title":"Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study","volume":"59","author":"Levy","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bbadis.2010.05.003_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"issue":"4","key":"10.1016\/j.bbadis.2010.05.003_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"issue":"4","key":"10.1016\/j.bbadis.2010.05.003_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbadis.2010.05.003_bib31","unstructured":"D. Levy, P.W. Wilson, K.M. Anderson, W.P. Castelli, Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am. Heart J. 119 (3 Pt 2) 71 (1990) 2-7."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry's disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur. Heart J."},{"issue":"455","key":"10.1016\/j.bbadis.2010.05.003_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1651-2227.2007.00207.x","article-title":"Vascular effects of sphingolipids","volume":"96","author":"Michel","year":"2007","journal-title":"Acta Paediatr. Suppl."},{"issue":"21","key":"10.1016\/j.bbadis.2010.05.003_bib35","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bbadis.2010.05.003_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J. Med."},{"issue":"7","key":"10.1016\/j.bbadis.2010.05.003_bib37","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS ONE"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443910000918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443910000918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T17:35:41Z","timestamp":1635356141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443910000918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0925443910000918"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2010.05.003","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}